

Synthesis of 2-substituted-6-hydroxy and 6-methoxy benzothiazoles from 1,4-benzoquinone

Giuseppe Meroni,^a Mehdi Rajabi,^a Paolo Ciana,^b Adriana Maggi,^b
and Enzo Santaniello*^a

^aLaboratory of Medical Chemistry, Department of Medicine, Surgery and Dentistry, Faculty of Medicine, Polo Universitario S. Paolo, Università degli Studi di Milano
via A. di Rudinì, 8, 20142 Milano, Italy

^bCenter of Excellence on Neurodegenerative Diseases, Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy

E-mail: enzo.santaniello@unimi.it

Abstract

A few 2-substituted-6-hydroxy and 6-methoxybenzothiazoles have been prepared from ethyl 6-hydroxybenzothiazole-2-carboxylate, obtained by oxidation of ethyl (*R*)-2-amino-3-(2,5-dihydroxyphenylsulfanyl)propanoate hydrochloride, in turn prepared from 1,4-benzoquinone.

Keywords: 2-substituted-6-hydroxybenzothiazoles, 2-substituted-6-methoxy benzothiazoles, 1,4-benzoquinone, ethyl 6-hydroxybenzothiazole-2-carboxylate, 2-cyano-6-methoxybenzothiazole

Introduction

The luciferase from the North American firefly *Photinus pyralis* (PpyLuc) catalyzes the conversion of D-luciferin [(*S*)-2-(6'-hydroxy-2'-benzothiazolyl)- Δ^2 -thiazoline-4-carboxylic acid] to oxyluciferin in the presence of ATP, Mg²⁺, and oxygen with production of a yellow-green light characterized by a broad emission spectrum and a peak at 560 nm (Figure 1).¹




Figure 1. Luciferase-catalyzed production of bioluminescence.

PpyLuc is a well characterized enzyme that finds a large number of biotechnological applications² and is, at present, the preferred enzyme for *in vivo* optical imaging of small animals.³ We have recently undertaken a project aimed to prepare compounds related to D-luciferin labelled with positron emitting fluorine (¹⁸F) for the *in vivo* imaging⁴ of a transgenic mouse that expresses a luciferase reporter gene under the control of activated estrogen receptors.⁵ We have considered the introduction of ¹⁸F into the benzothiazole core of D-luciferin (compounds **1**, Figure1) provided that affinity for PpyLuc could be demonstrated. 2,6-Disubstituted benzothiazoles (compounds **2a**) were required as intermediates for the preparation of compounds **1** or as potential probes for imaging, in view of the fact that compounds such as **2b** or **2c** are competitive inhibitors of luciferase.^{6,7}





Figure 2. Structure of compounds **1** and **2a-d**.

Within the above project, we have prepared a few compounds structurally related to compounds **2a** ($X=H$) and evaluated their *in vitro* affinity for PpyLuc.⁸ 2-Substituted-6-hydroxy and 6-methoxybenzothiazoles such as compounds **4a-d** (Scheme 1) were prepared from 2-cyano-6-methoxybenzothiazole **3** that is commercially available.




Scheme 1. Preparation of compounds **4a-d** and synthesis of D-luciferin from 2-cyano-6-methoxybenzothiazole **3**.

It should be mentioned that the nitrile **3** is an important intermediate for the synthesis of D-luciferin^{9,10} and that the synthesis of this compound has been the target of several publications.¹⁰⁻¹⁶ We report here the synthesis of a few 2-substituted-6-hydroxy and 6-methoxybenzothiazoles from ethyl 6-hydroxybenzothiazole-2-carboxylate, in turn obtained from 1,4-benzoquinone.


Results and discussion

The reaction of quinones and cysteine has been extensively studied¹⁷⁻¹⁹ and from 1,4-benzoquinone **5** ethyl (*R*)-2-amino-3-(2,5-dihydroxyphenylsulfanyl)propanoate hydrochloride **6** has been prepared and characterized.²⁰ The oxidation of the ester **6** has been studied by a few authors^{20,21} and the synthetic procedure most reliable from a preparative point of view is that recently described by Löwik et al.²¹ When the oxidation was carried out with potassium ferricyanide $K_3Fe(CN)_6$ in the presence of NaOH and methanol or ethanol, mixtures of the thiazines **7a** or **7b** and the ethyl ester **8** were obtained (Scheme 2). The thiazines **7a** or **7b** could be isolated by flash chromatography and converted into the benzothiazole ester **8** by treatment with 1 M HCl in methanol or ethanol. The ester **8** could also be obtained by acidic treatment of the crude mixtures **7a/8** or **7b/8**. We have prepared our 2-substituted-6-hydroxy and 6-methoxybenzothiazoles from ethyl (*R*)-2-amino-3-(2,5-dihydroxyphenylsulfanyl) propanoate hydrochloride **6** basically relying upon the original experimental protocol.²⁰ Specifically, we have carried out the reaction of 1,4-benzoquinone **5** with L-cysteine ethyl ester hydrochloride in methanol at room temperature, excluding water from the reaction. The ethyl ester **6** obtained after the work-up (95%) could be stored as a solid product²³ and later oxidized with $K_3Fe(CN)_6$ in aqueous NaOH in the presence of an alcohol, as described by Löwik et al.²¹ We have selected isopropanol²³ and carried out the reaction at room temperature. Purification of the crude mixture of products by silica gel column chromatography afforded the ester **8** essentially pure (68%). Furthermore, in order to avoid the high molar ratio (6:1) of $K_3Fe(CN)_6$ reported in the original procedure,²¹ we have attempted a few alternative oxidations.²⁴ Finally, we have found that the reaction of cupric salts with the ester **6** (molar ratio, 3:1) in isopropanol/water can constitute an alternative to the procedure involving $K_3Fe(CN)_6$.²⁵

The synthesis of 2-substituted 6-hydroxy and 6-methoxybenzothiazoles from the ester **8** is illustrated in Scheme 3. Thus, protection of the ester **8** as the corresponding 6-*O*-methyl ether **9** (92% yield) and following quantitative reaction with concentrated aqueous ammonia²⁶ afforded the amide **4a**. This amide could also be prepared by methylation of 2-carboxyamide-6-hydroxybenzothiazole **4c**, in turn obtained from the ester **8** by treatment with concentrated aqueous ammonia (98%). However, methylation of the amide **4c** was less straightforward, due to the formation of side products, presumably occurring from the methylation of the 2-carboxyamide function. Finally, the transformation of the amide **4a** into the nitrile **3** was carried out using $POCl_3$ as dehydrating agent (72% yield).²⁷



Scheme 2. Preparation and oxidation of the ester **8**. Reagents and conditions: (i) MeOH, room temperature, 1 h, 95%; (ii) K₃Fe(CN)₆, NaOH, aq. MeOH or EtOH, room temperature, 1 h, 58%; (iii) 1 N HCl, EtOH, room temperature, 24 h, 86%.



Scheme 3. Preparation of 2-substituted 6-hydroxy and 6-methoxybenzothiazoles from ethyl 6-hydroxybenzothiazole-2-carboxylate **8**. Reagents and conditions: (i) aq. K₃Fe(CN)₆, NaOH,

iPrOH, room temperature, 1.5 h; (ii) silica gel chromatography, 68%; (iii) CuBr₂ in iPrOH/H₂O, room temperature, 2 h, 65%; (iv) MeI/K₂CO₃/DMF, reflux, 1 h, 92%; (v) NH₄OH/EtOH, reflux, 5 h, 98%; (vi) POCl₃, Py/CH₂Cl₂, room temperature, 12 h, 72%.

Conclusions

We have reported a new approach to the synthesis of a few 2-substituted 6-hydroxy and 6-methoxybenzothiazoles starting from 1,4-benzoquinone **5**. Ethyl (*R*)-2-amino-3-(2,5-dihydroxyphenylsulfanyl)propanoate hydrochloride **6** has been prepared by an improved procedure and the oxidation of this intermediate to the benzothiazole ester **8** has been ameliorated. According to the experimental protocol outlined in our work, the key intermediate for the synthesis of D-luciferin, 2-cyano-6-methoxybenzothiazole **3**, can be prepared in 42 % yield. This is worth of note, since yields are higher than those obtained following the classical approach (9.9%)¹⁰ and comparable with the most convenient synthesis based on a Sandmeyer approach, using poisonous cyanides (48,6%).^{13,14} Finally, our synthetic approach opens the possibility of preparing 2,6-disubstituted benzothiazoles suitable for ¹⁸F labeling such as compounds **2a** starting from properly substituted 1,4-benzoquinones. Alternatively, from the ester **8** also new ¹⁸F-labeled amides **2d** may become available.

Experimental Section

General. Melting points were recorded on a Stuart Scientific SMP3 instrument and are uncorrected. ¹H- and ¹³C-NMR spectra were recorded at 303 K on a Bruker AM-500 spectrometer equipped with an Aspect 3000 computer, a process control and an array processor. The ¹H- and ¹³C chemical shifts are reported in parts per million, using as reference the signal for residual solvent. The progress of all reactions and column chromatography were monitored by TLC using Silica Gel 60 F₂₅₄ precoated plates with a fluorescent indicator (Merck). Purification of products by chromatography was performed using silica gel 60 (230-400 mesh, Merck). All reagents were obtained from commercial sources and used without further purification.

Ethyl (*R*)-2-amino-3-(2,5-dihydroxyphenylsulfanyl)propanoate hydrochloride **6.** A solution of 1,4-benzoquinone **5** (0.997 g, 9.24 mmol) in MeOH (20 mL) is added dropwise to a solution of L-cysteine ethyl ester hydrochloride (1.715 g, 9.24 mmol) in MeOH (10 mL) under nitrogen and stirring at room temperature (1.5 h). The reaction is monitored by TLC (petroleum ether/ethyl acetate, 6/4) and upon completion the solvent is evaporated. Ethyl acetate is added (10 mL) to wash the crude product and then is removed by decantation. The operation is repeated with diethyl ether and dichloromethane and the ester **6** is obtained as a solid. The ester **6** is a hygroscopic compound that can be obtained and stored at room temperature if ambient moisture

is properly excluded. A freshly prepared sample decomposes at 130 °C; ¹H-NMR (in CD₃OD) δ 1.12 (t, 3H), 3.32 (dd, 1H, *J*=4.9 and 15.6 Hz), 3.57 (dq, 1H, *J*=7.1 and 10.5 Hz), 3.82 (dd, 1H, *J*=4.4 and 15.3 Hz), 3.97 (dq, 1H, *J* = 7.1 and 10.5 Hz), 4.15 (m, 1H), 6.65 (dd, 1H, *J*=2.9 and 8.8 Hz), 6.70 (d, 1H, *J*=8.8 Hz), 6.85 (d, 1H, *J*=2.9 Hz); ¹³C-NMR (in CD₃OD) δ 12.2, 33.5, 51.5, 61.9, 115.6, 116.1, 116.8, 120.7, 149.9, 150.1, 166.9.

Ethyl 6-hydroxybenzothiazole-2-carboxylate 8. a. K₃Fe(CN)₆ oxidation. To a solution of the ester **6** (1.755 g, 5.98 mmol) in isopropanol (45 mL) an aqueous solution of 1 M K₃Fe(CN)₆ (36 mL) and 4 M NaOH (2.5 mL) is added. The mixture is stirred at room temperature (1.5 h) and monitored by TLC (dichloromethane/methanol, 95/5). At the end of the reaction, water is added and the product extracted with ethyl acetate, that is then washed with brine. After removal of the solvent at reduced pressure, the product is purified by column chromatography (petroleum ether/ethyl acetate, 7/3). Yield of compound **8**: 0.910 g (68%).

b. Reaction with Cu(II) salts. To a solution of the ester **6** (0.425 g, 1.45 mmol) in isopropanol (15 mL) an aqueous solution of CuBr₂ (0.965 g, 4.335 mmol) in water (15 mL) is added. The mixture is stirred at room temperature (2 h) and monitored by TLC (dichloromethane/methanol, 95/5). At the end of the reaction, water is added and the product extracted with ethyl acetate, that is then washed with brine. After removal of the solvent at reduced pressure, the ester **8** is purified by column chromatography (petroleum ether/ethyl acetate, 7/3). Yield: 0.210 g (65%); mp 178-180 °C (lit. 172-173 °C)²¹. ¹H-NMR (in DMSO) δ 1.35 (t, 3 H, *J*=7.2 Hz), 4.42 (q, 2 H, *J*=7.2 Hz), 7.10 (dd, 1H, *J*=2.5 and 9.0 Hz), 7.47 (d, 1H, *J*=2.5 Hz), 8.00 (dd, 1H, *J* = 2.5 and 9.0 Hz), 10.3 (s, 1H); ¹³C-NMR (in CD₃OD) δ 15.0, 62.6, 106.0, 118.0, 126.0, 139.1, 147.9, 155.8, 158.4, 161.0. *Anal.* Calcd. for C₁₀H₉NO₃S: C, 53.80; H, 4.06; N, 6.27; Found: C, 53.88; H, 4.12; N, 6.18.

Ethyl 6-methoxybenzothiazole-2-carboxylate 9. To a solution of the ester **8** (1.20 g, 5.38 mmol) in DMF (15 mL), potassium carbonate (1.115 g, 8.07 mmol) is added and the suspension stirred at room temperature (30 min). Methyl iodide (0.504 mL, 8.07 mmol) is added and the suspension is refluxed for 1h, monitoring the reaction by TLC (dichloromethane/methanol, 95/5). At the end, brine is added and the product is extracted with ethyl acetate. The organic solvent is removed to leave the pure ester **9** (1.172 g, 92%) as a yellow solid; mp 67-69 °C. ¹H-NMR (in CDCl₃) δ 1.48 (t, 3 H, *J*=8.7 Hz), 3.88 (s, 3H), 4.53 (q, 2 H, *J*=8.7 Hz), 7.15 (dd, 1H, *J*=2.5 and 9.0 Hz), 7.36 (d, 1H, *J*=2.5 Hz), 7.98 (d, 1H, 5-H, *J*=8.7 Hz), 8.08 (dd, 1H, *J* = 2.5 and 9.0 Hz); ¹³C-NMR (in CDCl₃) δ 15.00, 55.55, 62.60, 103.95, 118.00, 126.50, 139.05, 148.00, 156.10, 159.95, 161.00. *Anal.* Calcd. for C₁₁H₁₁NO₃S: C, 55.70; H, 4.64; N, 5.90; Found: C, 55.79; H, 4.72; N, 5.85.

6-Methoxybenzothiazole-2-carboxamide 4a. A solution of the ester **9** (1.100 g, 4.641 mmol) in ethanol (50 mL) is treated with concentrated aqueous ammonia (20 mL) and the mixture refluxed (5 h). The reaction is monitored by TLC (dichloromethane/methanol, 95/5) and at the end the reaction mixture is evaporated under vacuum. The residue is treated with

dichloromethane/methanol (8/2), filtered on Florisil (20 g) and the amide **4a** is crystallized from methanol/chloroform (1:10) as a brown solid (0.965 g, 98%); mp 248-250 °C dec (lit. 257-258 °C)²⁸; ¹H-NMR δ 3.85 (s, 3H), 7.20 (d, 1H, *J*=8.7 Hz), 7.75 (s, 1H), 7.98 (d, 1H, *J*=8.7 Hz), 7.95 [(bs, 1H) and 8.35 (bs, 1H), CONH₂]; ¹³C-NMR δ 55.60, 104.00, 117.90, 125.95, 138.65, 147.80, 156.70, 160.95, 166.10. *Anal.* Calcd. for C₉H₈N₂O₂S: C, 51.92; H, 3.85; N, 13.46. Found: C, 52.09; H, 3.93; N, 13.40.

2-Cyano-6-methoxybenzothiazole 3. To a solution containing the amide **4a** (0.95 g, 4.567 mmol) and imidazole (0.311 g, 4.567 mmol) in anhydrous pyridine (25 mL), cooled at -10°C under nitrogen, a solution of POCl₃ (0.835 mL, 9.134 mmol) in dichloromethane (5 mL) is added. The temperature is slowly raised and stirring is continued for 12 h, monitoring the reaction by TLC (petroleum ether/ethyl acetate, 8/2). At the end, dichloromethane is added, then water, and the organic phase is separated, the solvent removed and the crude purified by column chromatography (petroleum ether/ethyl acetate, 9/1). The nitrile **3** is obtained as a yellow solid (0.625 g, 72%); mp 129-130 °C (lit. 129-130 °C)¹¹. ¹H-NMR (in CDCl₃) δ 3.93 (s, 3H), 7.24 (dd, 1H, *J*=2.5 and 9.0 Hz), 7.36 (d, 1H, *J*=2.5 Hz), 8.08 (dd, 1H, *J*=2.5 and 9.0 Hz); ¹³C-NMR (in CDCl₃) δ 56.7, 103.7, 113.9, 119.2, 126.5, 134.0, 138.1, 147.6, 161.2. *Anal.* Calcd. for C₉H₆N₂OS: C, 56.82; H, 3.18; N, 14.73; Found: C, 56.86; H, 3.22; N, 14.68.

Acknowledgements

This work has been financially supported by the European Project EMIL (European Molecular Imaging Laboratories, LSHC-Ct-2004-503569) entitled "Molecular Imaging for Early Detection of Tumors and Monitoring of Treatment".

References and Notes

1. White, E. H.; Rapaport, E.; Seliger, H. H.; Hopkins, T. A. *Bioorg. Chem.* **1971**, *1*, 92.
2. Roda, A.; Pasini, P.; Mirasoli, M.; Michelini, E.; Guardigli, M. *Trends Biotechnol.* **2004**, *22*, 295.
3. (a) Söling, A.; Rainov, N.G. *Expert. Opin. Biol. Ther.* **2003**, *3*, 1163. (b) Lüker, G.D.; Lüker, K. E. *J. Nucl. Med.* **2008**, *49*, 1.
4. (a) Ametamey, S.M.; Honer, M.; Schubiger, P.A. *Chem. Rev.* **2008**, *108*, 1501. (b) Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. *Angew. Chem. Int. Ed.* **2008**, *47*, 8998.
5. Ciana, P.; Raviscioni, M.; Mussi, P.; Vegeto, E.; Que, I.; Parker, M. G.; Lowik, C.; Maggi, A. *Nat. Med.* **2003**, *9*, 82.
6. Denburg, J. L.; Lee, R. T.; McElroy, W. D. *Archiv. Biochem. Biophys.* **1969**, *134*, 381.
7. Auld, D. S.; Southall, N. T.; Jadhav, A.; Johnson, R. L.; Diller, D. J.; Simeonov, A.; Austin, C. P.; Inglese, J. *J. Med. Chem.* **2008**, *51*, 2372.

8. Meroni, G.; Ciana, P.; Meda, C.; Maggi, A.; Santaniello, E. *Arkivoc* **2009**, (xi), 22.
9. White, E. H.; McCapra, F.; Field, G. F.; McElroy, W. D. *J. Am. Chem. Soc.* **1961**, 83, 2402.
10. White, E. H.; McCapra, F.; Field, G. F.; *J. Am. Chem. Soc.* **1963**, 85, 337.
11. Seto, S.; Ogura, K.; Nishiyama, Y. *Bull. Chem. Soc. Jpn.* **1963**, 36, 332.
12. Bowie, L. *J. Methods. Enzymol.* **1978**, 57, 15.
13. Suzuki, N.; Nomoto, T., Kanamori, N.; Yoda, B.; Saeki, A. *Biosci. Biotech. Bioch.* **1993**, 57, 1561.
14. Toya, Y.; Takagi, M.; Nakata, H.; Suzuki, N.; Isobe, M.; Goto, T. *Bull. Chem. Soc. Jpn.* **1992**, 65, 392.
15. Bénéteau, V.; Besson, T.; Rees, C. W. *Synthetic Commun.* **1997**, 27, 2275.
16. Meroni, G.; Rajabi, M.; Santaniello, E. *Arkivoc* **2009**, (i), 265.
17. Kuhn, R.; Beinert, H. *Chem. Ber.* **1944**, 77, 606.
18. Prota, G.; Ponsiglione, E. *Tetrahedron. Lett.* **1972**, 13, 1327.
19. Crescenzi, O.; Prota, G.; Schultz, T.; Wolfram, L. J. *Tetrahedron* **1988**, 44, 6447.
20. Crescenzi, O.; Prota, G.; Schultz, T.; Wolfram, L. J. *Gazz. Chim. It.* **1990**, 120, 21.
21. Löwik, D. W. P. M.; Tisi, L. C.; Murray, J. A. H.; Lowe, C. R. *Synthesis* **2001**, 1780.
22. When the reaction of 1,4-benzoquinone and L-cysteine ethyl ester hydrochloride was carried out in aqueous methanol the ester **6** was recovered as a hygroscopic compound (see reference **20**). According to our procedure, a solid can be obtained and stored at room temperature if ambient moisture is properly excluded.
23. In reference 21, it was reported that when the oxidation of the ester **6** was carried out in isopropanol with $K_3Fe(CN)_6$ and NaOH, the corresponding benzothiazine could not be isolated by silica gel chromatography. In fact, in these conditions the compound was directly transformed into the benzothiazole ester **8**.
24. The reaction of the 1,4-benzoquinone portion of rifamycin S with cysteine methyl ester and following oxidation bring to the formation of a benzothiazole system; see: (a) Cricchio, R. *Tetrahedron.* **1980**, 36, 1415. (b) Cricchio, R. *Tetrahedron* **1980**, 36, 2009. Accordingly, we have used a few oxidants reported in these works (DDQ, MnO_2 , 1,4-benzoquinone) and other reagents such as Dess-Martin, pyridinium chlorochromate, or sodium chlorite. However, in general, unsatisfactory results were obtained.
25. For other examples of use of cupric salts for the synthesis of benzothiazoles, see: (a) Moghaddam, F. M.; Ismaili, H.; Bardajee, G. R. *Heteroatom Chem.* **2006**, 17, 136; (b) Meshram, H. M.; Kumar, D. A.; Prasad, R. V. *Synthetic Commun.* **2009**, 39, 2317.
26. Liso, G.; Trapani, G.; Latrofa, A. *J. Heterocyclic Chem.* **1987**, 24, 1683.
27. Van der Veken, P.; Senten, K.; Kertész, I.; De Meester, I.; Lambeir, A. M.; Maes, M. B.; Scharpé, S.; Haemers, A.; Augustyns, K. *J. Med. Chem.* **2005**, 48, 1768.
28. Yarovenko, V. N.; Stoyanovich, F. M.; Zolotarskaya, O. Y.; Chernoburova, E. I.; Zavarzin, I. V.; Krayushkin, M. M. *Russ. Chem. Bull. Int. Ed.* **2002**, 51, 144.